Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by ZyVersa Therapeutics
< Previous
1
2
Next >
ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update
August 09, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation
August 07, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults
July 29, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100
July 25, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model
July 18, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 3rd Annual Kidney Conference to be Held Virtually on July 15, 2024
July 09, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update
May 15, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention
May 14, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease
April 29, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes
April 04, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
March 25, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease
March 18, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024
March 14, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity
February 29, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications
February 28, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option
February 22, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases
February 14, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key Milestones
February 07, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes
January 31, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer’s Disease
January 24, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Negative Breast Cancer Brain Metastasis
January 17, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics’ CEO, Stephen C. Glover, Featured on Benzinga All Access
January 10, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital Markets
January 04, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Providing Outlook for 2024
January 03, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2024”
December 18, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200
December 14, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease in Patients with Type 2 Diabetes
December 07, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million Public Offering
December 06, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100’s Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways
December 06, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
ZyVersa Therapeutics, Inc. Announces Reverse Stock Split and Increase in Authorized Shares of Common Stock
November 30, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tickers
ZVSA
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.